Heart failure with preserved ejection fraction (HFpEF) continues to be a complex condition lacking effective evidence-based treatment for many years, thus creating the opportunity to investigate effectiveness of SGLT2 inhibitors in HFpEF. This evidence concerns the gene SLC5A2 and heart failure.